Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans
Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer mortality and the incidence is projected to increase by 2030. Despite recent advances in its treatment, African Americans have a 50-60% higher incidence and 30% higher mortality rate when compared to European Amer...
Gespeichert in:
| Veröffentlicht in: | Journal of the National Medical Association 2023-04, Vol.115 (2), p.164-174 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 174 |
|---|---|
| container_issue | 2 |
| container_start_page | 164 |
| container_title | Journal of the National Medical Association |
| container_volume | 115 |
| creator | Telisnor, Guettchina DeRemer, David L. Frimpong, Esther Agyare, Edward Allen, John Ricks-Santi, Luisel Han, Bo George, Thomas Rogers, Sherise C. |
| description | Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer mortality and the incidence is projected to increase by 2030. Despite recent advances in its treatment, African Americans have a 50-60% higher incidence and 30% higher mortality rate when compared to European Americans possibly resulting from differences in socioeconomic status, access to healthcare, and genetics. Genetics plays a role in cancer predisposition, response to cancer therapeutics (pharmacogenetics), and in tumor behavior, making some genes targets for oncologic therapeutics. We hypothesize that the germline genetic differences in predisposition, drug response, and targeted therapies also impact PDAC disparities. To demonstrate the impact of genetics and pharmacogenetics on PDAC disparities, a review of the literature was performed using PubMed with variations of the following keywords: pharmacogenetics, pancreatic cancer, race, ethnicity, African, Black, toxicity, and the FDA-approved drug names: Fluoropyrimidines, Topoisomerase inhibitors, Gemcitabine, Nab-Paclitaxel, Platinum agents, Pembrolizumab, PARP-inhibitors, and NTRK fusion inhibitors. Our findings suggest that the genetic profiles of African Americans may contribute to disparities related to FDA approved chemotherapeutic response for patients with PDAC. We recommend a strong focus on improving genetic testing and participation in biobank sample donations for African Americans. In this way, we can improve our current understanding of genes that influence drug response for patients with PDAC. |
| doi_str_mv | 10.1016/j.jnma.2023.01.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10639003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0027968423000172</els_id><sourcerecordid>2778974702</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-2d266e2cd4b429c67f857cb14647e8c1832fbc20c77769f7b766efb2965829c93</originalsourceid><addsrcrecordid>eNp9kUuLFDEURoMoTtv6B1xIgRs3VSapdB4gSDP4ggFBdB1SqZvuFF1JmVTPODt_uim7Z1AXrnKTnPtxk4PQc4Ibggl_PTRDGE1DMW0bTBqM5QO0Ioq1NeOqfYhWGFNRKy7ZBXqS84ALoTabx-ii5RITwuQK_fwC1x5uquiqHQSYva1M6Ktpb9JobLw7671zkCBYyJUPlb2d4xx_nOHZpB3MUIo9JDP5wriYqskEm8As7baUkJbOrUu-7KrtCL-L_BQ9cuaQ4dl5XaNv7999vfxYX33-8Olye1VbJtlc055yDtT2rGNUWS6c3AjbEcaZAGmJbKnrLMVWCMGVE50ouOuo4htZeNWu0dtT7nTsRugthDmZg56SH0261dF4_fdN8Hu9i9eaYN4qjNuS8OqckOL3I-RZjz5bOBxMgHjMmgohlWCi6Fijl_-gQzymUN6nqWRSldkVKRQ9UTbFnBO4-2kI1othPejFsF4Ma0x08VeaXvz5jvuWO6UFeHMCoPxmcZt0tn4x1_sEdtZ99P_L_wUfG7m0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2848985791</pqid></control><display><type>article</type><title>Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Telisnor, Guettchina ; DeRemer, David L. ; Frimpong, Esther ; Agyare, Edward ; Allen, John ; Ricks-Santi, Luisel ; Han, Bo ; George, Thomas ; Rogers, Sherise C.</creator><creatorcontrib>Telisnor, Guettchina ; DeRemer, David L. ; Frimpong, Esther ; Agyare, Edward ; Allen, John ; Ricks-Santi, Luisel ; Han, Bo ; George, Thomas ; Rogers, Sherise C.</creatorcontrib><description>Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer mortality and the incidence is projected to increase by 2030. Despite recent advances in its treatment, African Americans have a 50-60% higher incidence and 30% higher mortality rate when compared to European Americans possibly resulting from differences in socioeconomic status, access to healthcare, and genetics. Genetics plays a role in cancer predisposition, response to cancer therapeutics (pharmacogenetics), and in tumor behavior, making some genes targets for oncologic therapeutics. We hypothesize that the germline genetic differences in predisposition, drug response, and targeted therapies also impact PDAC disparities. To demonstrate the impact of genetics and pharmacogenetics on PDAC disparities, a review of the literature was performed using PubMed with variations of the following keywords: pharmacogenetics, pancreatic cancer, race, ethnicity, African, Black, toxicity, and the FDA-approved drug names: Fluoropyrimidines, Topoisomerase inhibitors, Gemcitabine, Nab-Paclitaxel, Platinum agents, Pembrolizumab, PARP-inhibitors, and NTRK fusion inhibitors. Our findings suggest that the genetic profiles of African Americans may contribute to disparities related to FDA approved chemotherapeutic response for patients with PDAC. We recommend a strong focus on improving genetic testing and participation in biobank sample donations for African Americans. In this way, we can improve our current understanding of genes that influence drug response for patients with PDAC.</description><identifier>ISSN: 0027-9684</identifier><identifier>EISSN: 1943-4693</identifier><identifier>DOI: 10.1016/j.jnma.2023.01.008</identifier><identifier>PMID: 36801148</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>African Americans ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Black or African American - genetics ; Cancer therapies ; Carcinoma, Pancreatic Ductal - drug therapy ; Carcinoma, Pancreatic Ductal - ethnology ; Carcinoma, Pancreatic Ductal - genetics ; Carcinoma, Pancreatic Ductal - pathology ; Cytotoxicity ; Data analysis ; Diarrhea ; Disparities2 ; DNA repair ; DPD5 ; Enzymes ; Equity6 ; Genes ; Humans ; Kinases ; Medical prognosis ; Metabolism ; Molecular Targeted Therapy - methods ; Mutation ; Neutropenia ; Pancreatic cancer ; Pancreatic cancer3 ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - ethnology ; Pancreatic Neoplasms - genetics ; Pancreatic Neoplasms - pathology ; Pharmacogenetics ; Pharmacogenetics1 ; Toxicity ; UGT1A14</subject><ispartof>Journal of the National Medical Association, 2023-04, Vol.115 (2), p.164-174</ispartof><rights>2023</rights><rights>Published by Elsevier Inc.</rights><rights>Copyright Elsevier Limited Apr 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-2d266e2cd4b429c67f857cb14647e8c1832fbc20c77769f7b766efb2965829c93</citedby><cites>FETCH-LOGICAL-c484t-2d266e2cd4b429c67f857cb14647e8c1832fbc20c77769f7b766efb2965829c93</cites><orcidid>0000-0003-4764-0171 ; 0000-0002-2207-9552 ; 0000-0002-6249-9180</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36801148$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Telisnor, Guettchina</creatorcontrib><creatorcontrib>DeRemer, David L.</creatorcontrib><creatorcontrib>Frimpong, Esther</creatorcontrib><creatorcontrib>Agyare, Edward</creatorcontrib><creatorcontrib>Allen, John</creatorcontrib><creatorcontrib>Ricks-Santi, Luisel</creatorcontrib><creatorcontrib>Han, Bo</creatorcontrib><creatorcontrib>George, Thomas</creatorcontrib><creatorcontrib>Rogers, Sherise C.</creatorcontrib><title>Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans</title><title>Journal of the National Medical Association</title><addtitle>J Natl Med Assoc</addtitle><description>Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer mortality and the incidence is projected to increase by 2030. Despite recent advances in its treatment, African Americans have a 50-60% higher incidence and 30% higher mortality rate when compared to European Americans possibly resulting from differences in socioeconomic status, access to healthcare, and genetics. Genetics plays a role in cancer predisposition, response to cancer therapeutics (pharmacogenetics), and in tumor behavior, making some genes targets for oncologic therapeutics. We hypothesize that the germline genetic differences in predisposition, drug response, and targeted therapies also impact PDAC disparities. To demonstrate the impact of genetics and pharmacogenetics on PDAC disparities, a review of the literature was performed using PubMed with variations of the following keywords: pharmacogenetics, pancreatic cancer, race, ethnicity, African, Black, toxicity, and the FDA-approved drug names: Fluoropyrimidines, Topoisomerase inhibitors, Gemcitabine, Nab-Paclitaxel, Platinum agents, Pembrolizumab, PARP-inhibitors, and NTRK fusion inhibitors. Our findings suggest that the genetic profiles of African Americans may contribute to disparities related to FDA approved chemotherapeutic response for patients with PDAC. We recommend a strong focus on improving genetic testing and participation in biobank sample donations for African Americans. In this way, we can improve our current understanding of genes that influence drug response for patients with PDAC.</description><subject>African Americans</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Black or African American - genetics</subject><subject>Cancer therapies</subject><subject>Carcinoma, Pancreatic Ductal - drug therapy</subject><subject>Carcinoma, Pancreatic Ductal - ethnology</subject><subject>Carcinoma, Pancreatic Ductal - genetics</subject><subject>Carcinoma, Pancreatic Ductal - pathology</subject><subject>Cytotoxicity</subject><subject>Data analysis</subject><subject>Diarrhea</subject><subject>Disparities2</subject><subject>DNA repair</subject><subject>DPD5</subject><subject>Enzymes</subject><subject>Equity6</subject><subject>Genes</subject><subject>Humans</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Mutation</subject><subject>Neutropenia</subject><subject>Pancreatic cancer</subject><subject>Pancreatic cancer3</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - ethnology</subject><subject>Pancreatic Neoplasms - genetics</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pharmacogenetics</subject><subject>Pharmacogenetics1</subject><subject>Toxicity</subject><subject>UGT1A14</subject><issn>0027-9684</issn><issn>1943-4693</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUuLFDEURoMoTtv6B1xIgRs3VSapdB4gSDP4ggFBdB1SqZvuFF1JmVTPODt_uim7Z1AXrnKTnPtxk4PQc4Ibggl_PTRDGE1DMW0bTBqM5QO0Ioq1NeOqfYhWGFNRKy7ZBXqS84ALoTabx-ii5RITwuQK_fwC1x5uquiqHQSYva1M6Ktpb9JobLw7671zkCBYyJUPlb2d4xx_nOHZpB3MUIo9JDP5wriYqskEm8As7baUkJbOrUu-7KrtCL-L_BQ9cuaQ4dl5XaNv7999vfxYX33-8Olye1VbJtlc055yDtT2rGNUWS6c3AjbEcaZAGmJbKnrLMVWCMGVE50ouOuo4htZeNWu0dtT7nTsRugthDmZg56SH0261dF4_fdN8Hu9i9eaYN4qjNuS8OqckOL3I-RZjz5bOBxMgHjMmgohlWCi6Fijl_-gQzymUN6nqWRSldkVKRQ9UTbFnBO4-2kI1othPejFsF4Ma0x08VeaXvz5jvuWO6UFeHMCoPxmcZt0tn4x1_sEdtZ99P_L_wUfG7m0</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Telisnor, Guettchina</creator><creator>DeRemer, David L.</creator><creator>Frimpong, Esther</creator><creator>Agyare, Edward</creator><creator>Allen, John</creator><creator>Ricks-Santi, Luisel</creator><creator>Han, Bo</creator><creator>George, Thomas</creator><creator>Rogers, Sherise C.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>4U-</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4764-0171</orcidid><orcidid>https://orcid.org/0000-0002-2207-9552</orcidid><orcidid>https://orcid.org/0000-0002-6249-9180</orcidid></search><sort><creationdate>20230401</creationdate><title>Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans</title><author>Telisnor, Guettchina ; DeRemer, David L. ; Frimpong, Esther ; Agyare, Edward ; Allen, John ; Ricks-Santi, Luisel ; Han, Bo ; George, Thomas ; Rogers, Sherise C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-2d266e2cd4b429c67f857cb14647e8c1832fbc20c77769f7b766efb2965829c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>African Americans</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Black or African American - genetics</topic><topic>Cancer therapies</topic><topic>Carcinoma, Pancreatic Ductal - drug therapy</topic><topic>Carcinoma, Pancreatic Ductal - ethnology</topic><topic>Carcinoma, Pancreatic Ductal - genetics</topic><topic>Carcinoma, Pancreatic Ductal - pathology</topic><topic>Cytotoxicity</topic><topic>Data analysis</topic><topic>Diarrhea</topic><topic>Disparities2</topic><topic>DNA repair</topic><topic>DPD5</topic><topic>Enzymes</topic><topic>Equity6</topic><topic>Genes</topic><topic>Humans</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Mutation</topic><topic>Neutropenia</topic><topic>Pancreatic cancer</topic><topic>Pancreatic cancer3</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - ethnology</topic><topic>Pancreatic Neoplasms - genetics</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pharmacogenetics</topic><topic>Pharmacogenetics1</topic><topic>Toxicity</topic><topic>UGT1A14</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Telisnor, Guettchina</creatorcontrib><creatorcontrib>DeRemer, David L.</creatorcontrib><creatorcontrib>Frimpong, Esther</creatorcontrib><creatorcontrib>Agyare, Edward</creatorcontrib><creatorcontrib>Allen, John</creatorcontrib><creatorcontrib>Ricks-Santi, Luisel</creatorcontrib><creatorcontrib>Han, Bo</creatorcontrib><creatorcontrib>George, Thomas</creatorcontrib><creatorcontrib>Rogers, Sherise C.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the National Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Telisnor, Guettchina</au><au>DeRemer, David L.</au><au>Frimpong, Esther</au><au>Agyare, Edward</au><au>Allen, John</au><au>Ricks-Santi, Luisel</au><au>Han, Bo</au><au>George, Thomas</au><au>Rogers, Sherise C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans</atitle><jtitle>Journal of the National Medical Association</jtitle><addtitle>J Natl Med Assoc</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>115</volume><issue>2</issue><spage>164</spage><epage>174</epage><pages>164-174</pages><issn>0027-9684</issn><eissn>1943-4693</eissn><abstract>Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer mortality and the incidence is projected to increase by 2030. Despite recent advances in its treatment, African Americans have a 50-60% higher incidence and 30% higher mortality rate when compared to European Americans possibly resulting from differences in socioeconomic status, access to healthcare, and genetics. Genetics plays a role in cancer predisposition, response to cancer therapeutics (pharmacogenetics), and in tumor behavior, making some genes targets for oncologic therapeutics. We hypothesize that the germline genetic differences in predisposition, drug response, and targeted therapies also impact PDAC disparities. To demonstrate the impact of genetics and pharmacogenetics on PDAC disparities, a review of the literature was performed using PubMed with variations of the following keywords: pharmacogenetics, pancreatic cancer, race, ethnicity, African, Black, toxicity, and the FDA-approved drug names: Fluoropyrimidines, Topoisomerase inhibitors, Gemcitabine, Nab-Paclitaxel, Platinum agents, Pembrolizumab, PARP-inhibitors, and NTRK fusion inhibitors. Our findings suggest that the genetic profiles of African Americans may contribute to disparities related to FDA approved chemotherapeutic response for patients with PDAC. We recommend a strong focus on improving genetic testing and participation in biobank sample donations for African Americans. In this way, we can improve our current understanding of genes that influence drug response for patients with PDAC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36801148</pmid><doi>10.1016/j.jnma.2023.01.008</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-4764-0171</orcidid><orcidid>https://orcid.org/0000-0002-2207-9552</orcidid><orcidid>https://orcid.org/0000-0002-6249-9180</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0027-9684 |
| ispartof | Journal of the National Medical Association, 2023-04, Vol.115 (2), p.164-174 |
| issn | 0027-9684 1943-4693 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10639003 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | African Americans Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Black or African American - genetics Cancer therapies Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - ethnology Carcinoma, Pancreatic Ductal - genetics Carcinoma, Pancreatic Ductal - pathology Cytotoxicity Data analysis Diarrhea Disparities2 DNA repair DPD5 Enzymes Equity6 Genes Humans Kinases Medical prognosis Metabolism Molecular Targeted Therapy - methods Mutation Neutropenia Pancreatic cancer Pancreatic cancer3 Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - ethnology Pancreatic Neoplasms - genetics Pancreatic Neoplasms - pathology Pharmacogenetics Pharmacogenetics1 Toxicity UGT1A14 |
| title | Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T02%3A20%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20of%20genetic%20and%20pharmacogenetic%20differences%20in%20cytotoxic%20and%20targeted%20therapies%20for%20pancreatic%20cancer%20in%20African%20Americans&rft.jtitle=Journal%20of%20the%20National%20Medical%20Association&rft.au=Telisnor,%20Guettchina&rft.date=2023-04-01&rft.volume=115&rft.issue=2&rft.spage=164&rft.epage=174&rft.pages=164-174&rft.issn=0027-9684&rft.eissn=1943-4693&rft_id=info:doi/10.1016/j.jnma.2023.01.008&rft_dat=%3Cproquest_pubme%3E2778974702%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2848985791&rft_id=info:pmid/36801148&rft_els_id=S0027968423000172&rfr_iscdi=true |